IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models
/in Dendritic Cells, International Publications /von 2010-09-07 / Cancer Res. 2010 Sep;70(18):7093-101Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-14Dendritic cell vaccination of patients with metastatic colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2010-09-01 / Dan Med Bull 2010 Sep;57(9):B4171Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-09-01 / PLoS ONE 2010 Sep;5(9)Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-78Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-75Prostate cancer as a model for tumour immunotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-93Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy
/in Dendritic Cells, International Publications /von 2010-08-01 / BioSystems 2010 Aug;101(2):117-26[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-704
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution